This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Dec 11;376(9757):1983-4; author reply 1984-5.

doi: 10.1016/S0140-6736(10)62254-4.

Termination of the CRESCENDO trial

Dominique Roberfroid, Carl Lachat, Catherine Lucet

PMID: 21146095
DOI: 10.1016/S0140-6736(10)62254-4

Comment

Termination of the CRESCENDO trial

Dominique Roberfroid et al. Lancet. 2010.

. 2010 Dec 11;376(9757):1983-4; author reply 1984-5.

doi: 10.1016/S0140-6736(10)62254-4.

Authors

Dominique Roberfroid, Carl Lachat, Catherine Lucet

PMID: 21146095
DOI: 10.1016/S0140-6736(10)62254-4

No abstract available

PubMed Disclaimer

Comment on

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators. Topol EJ, et al. Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X. Lancet. 2010. PMID: 20709233 Clinical Trial.

Similar articles

Termination of the CRESCENDO trial.
Kwatra SG. Kwatra SG. Lancet. 2010 Dec 11;376(9757):1984; author reply 1984-5. doi: 10.1016/S0140-6736(10)62255-6. Lancet. 2010. PMID: 21146097 No abstract available.
[Antiobesity drugs--new limitations].
Nau JY. Nau JY. Rev Med Suisse. 2007 Nov 28;3(135):2753. Rev Med Suisse. 2007. PMID: 18214233 French. No abstract available.
The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
Kintscher U. Kintscher U. Eur Heart J. 2008 Jul;29(14):1709-10. doi: 10.1093/eurheartj/ehn255. Epub 2008 Jun 13. Eur Heart J. 2008. PMID: 18556715 No abstract available.
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Christensen R, et al. Lancet. 2007 Nov 17;370(9600):1706-13. doi: 10.1016/S0140-6736(07)61721-8. Lancet. 2007. PMID: 18022033 Review.
[Drug treatment of obesity].
Svendsen OL, Toubro S, Breum L, Bruun JM, Astrup AV. Svendsen OL, et al. Ugeskr Laeger. 2006 Jan 9;168(2):163-7. Ugeskr Laeger. 2006. PMID: 16403342 Review. Danish.

See all similar articles

Cited by

The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.
Brezing CA, Levin FR. Brezing CA, et al. Neuropsychopharmacology. 2018 Jan;43(1):173-194. doi: 10.1038/npp.2017.212. Epub 2017 Sep 6. Neuropsychopharmacology. 2018. PMID: 28875989 Free PMC article. Review.
Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction.
Barton M, Baretella O, Meyer MR. Barton M, et al. Br J Pharmacol. 2012 Feb;165(3):591-602. doi: 10.1111/j.1476-5381.2011.01472.x. Br J Pharmacol. 2012. PMID: 21557734 Free PMC article. Review.
Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.
Kesner AJ, Lovinger DM. Kesner AJ, et al. J Neurochem. 2021 Jun;157(5):1674-1696. doi: 10.1111/jnc.15369. Epub 2021 May 16. J Neurochem. 2021. PMID: 33891706 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information